TWI324934B - Pharmaceutical compositions for the treatment of asthma - Google Patents

Pharmaceutical compositions for the treatment of asthma Download PDF

Info

Publication number
TWI324934B
TWI324934B TW91119250A TW91119250A TWI324934B TW I324934 B TWI324934 B TW I324934B TW 91119250 A TW91119250 A TW 91119250A TW 91119250 A TW91119250 A TW 91119250A TW I324934 B TWI324934 B TW I324934B
Authority
TW
Taiwan
Prior art keywords
asthma
treatment
pharmaceutical compositions
processes
invention relates
Prior art date
Application number
TW91119250A
Inventor
A Sequeira Joel
A Sharpe Stefan
L Hart John
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US31538601P priority Critical
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of TWI324934B publication Critical patent/TWI324934B/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI324934(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Abstract

The invention relates to aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol fumarate and processes for preparing same.
TW91119250A 2001-08-28 2002-08-26 Pharmaceutical compositions for the treatment of asthma TWI324934B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US31538601P true 2001-08-28 2001-08-28

Publications (1)

Publication Number Publication Date
TWI324934B true TWI324934B (en) 2010-05-21

Family

ID=23224164

Family Applications (1)

Application Number Title Priority Date Filing Date
TW91119250A TWI324934B (en) 2001-08-28 2002-08-26 Pharmaceutical compositions for the treatment of asthma

Country Status (27)

Country Link
US (3) US20030114428A1 (en)
EP (3) EP1420759B1 (en)
JP (3) JP2005502675A (en)
KR (1) KR100970531B1 (en)
CN (2) CN1649568B (en)
AR (1) AR036358A1 (en)
AT (2) AT430555T (en)
AU (1) AU2002313828B2 (en)
BR (1) BR0212089A (en)
CA (1) CA2457926A1 (en)
CO (1) CO5560551A2 (en)
CY (2) CY1109212T1 (en)
DE (2) DE60239648D1 (en)
DK (2) DK1420759T3 (en)
ES (3) ES2389480T3 (en)
HK (3) HK1060972A1 (en)
HU (1) HU0401514A3 (en)
MX (1) MXPA04001875A (en)
NO (1) NO20041277L (en)
NZ (1) NZ530987A (en)
PE (1) PE03902003A1 (en)
PL (1) PL209640B1 (en)
PT (2) PT1420759E (en)
SI (2) SI2092935T1 (en)
TW (1) TWI324934B (en)
WO (1) WO2003020253A2 (en)
ZA (1) ZA200401419B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
HU229798B1 (en) * 2001-03-30 2014-07-28 Jagotec Ag Medical aerosol compositions and process for their preparation
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
ES2388537T3 (en) * 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. metered dose inhaler containing a suspension formulation of aerosol
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
JP4679901B2 (en) * 2002-08-27 2011-05-11 シェーリング コーポレイションSchering Corporation Process for producing a metered dose inhaler formulation
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CN1870976A (en) * 2003-10-20 2006-11-29 先灵公司 Pharmaceutical compositions
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
WO2005072704A2 (en) * 2004-01-21 2005-08-11 Schering Corporation Method of treating acute rhinosinusitis
US20110053999A1 (en) 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
US9808423B2 (en) * 2004-10-12 2017-11-07 Generics [Uk] Limited Preparation of suspension aerosol formulations
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
US20070203104A1 (en) * 2006-02-09 2007-08-30 Chaudhry Saeed M Pharmaceutical Formulations
AU2007346134A1 (en) * 2007-02-09 2008-08-14 Merck Sharp & Dohme Corp. Stable pharmaceutical drug aerosols
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
US20110182830A1 (en) * 2008-01-10 2011-07-28 Schering Corporation Inhalation drug products, systems and uses
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP3508239A1 (en) 2009-05-18 2019-07-10 Boehringer Ingelheim International GmbH Adapter, inhalant apparatus and atomizer
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
RU2580315C2 (en) * 2009-05-29 2016-04-10 Перл Терапьютикс, Инк. Compositions for respiratory delivery of active substances and methods and systems connected therewith
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
KR101782306B1 (en) 2009-11-25 2017-09-27 베링거 인겔하임 인터내셔날 게엠베하 Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
ES2646201T3 (en) * 2009-12-07 2017-12-12 Horizon Orphan Llc Formulations 4-methylpyrazole
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
WO2012130757A1 (en) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
CN103874483B (en) * 2011-10-11 2017-09-12 奇斯药制品公司 Coated crystal particles β- agonist fatty acids
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
EP2835146A1 (en) 2013-08-09 2015-02-11 Boehringer Ingelheim International GmbH Nebulizer with blocking mechanism
JP2016527041A (en) 2013-08-09 2016-09-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
AU2015257878B2 (en) 2014-05-07 2019-08-08 Boehringer Ingelheim International Gmbh Container, nebulizer and use
CN106232165A (en) 2014-05-07 2016-12-14 勃林格殷格翰国际有限公司 Container, indicator device, and nebulizer
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
CA3016890A1 (en) * 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658A (en) * 2016-12-28 2017-05-10 四川普锐特医药科技有限责任公司 Medical aerosol preparation and quantitatively-inhaled aerosol

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1992022288A1 (en) * 1991-06-10 1992-12-23 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
MY131733A (en) * 1994-12-22 2007-08-30 Astra Ab Aerosol drug formulations
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
CN1162157C (en) * 1996-08-29 2004-08-18 先灵公司 Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (en) * 1999-01-28 2002-09-04 Schering Corp CARRIER AND METHOD FOR solid particulate provide control of particulate size distribution FOR PARTICLE AND CONVERTIBLE amorphous content during preparation
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (en) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
ES2220724T3 (en) * 2000-01-20 2004-12-16 Basilea Pharmaceutica Ag Administrable compositions cyclic peptides nasally.
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
WO2002011711A2 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Squibb Bristol Myers Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
US20030114428A1 (en) 2003-06-19
HU0401514A3 (en) 2012-08-28
EP1420759B1 (en) 2009-05-06
DK2092935T3 (en) 2011-07-18
HU0401514A2 (en) 2004-12-28
EP2319494A1 (en) 2011-05-11
US20100143269A1 (en) 2010-06-10
BR0212089A (en) 2004-08-03
CN1649568B (en) 2010-10-27
DE60239648D1 (en) 2011-05-12
PL368897A1 (en) 2005-04-04
PE03902003A1 (en) 2003-04-24
HK1151987A1 (en) 2012-10-12
CN101856362A (en) 2010-10-13
WO2003020253A3 (en) 2003-05-22
DE60232251D1 (en) 2009-06-18
AT503461T (en) 2011-04-15
EP2092935B1 (en) 2011-03-30
NO20041277L (en) 2004-03-26
HK1060972A1 (en) 2009-07-17
PT2092935E (en) 2011-05-31
CY1109212T1 (en) 2014-07-02
PL209640B1 (en) 2011-09-30
JP5170789B2 (en) 2013-03-27
PT1420759E (en) 2009-06-30
EP2092935A1 (en) 2009-08-26
AU2002313828B2 (en) 2005-09-08
ES2325316T3 (en) 2009-09-01
AR036358A1 (en) 2004-09-01
KR20040031002A (en) 2004-04-09
WO2003020253A2 (en) 2003-03-13
EP1420759A2 (en) 2004-05-26
JP2009185075A (en) 2009-08-20
CO5560551A2 (en) 2005-09-30
SI2092935T1 (en) 2011-07-29
ES2389480T3 (en) 2012-10-26
CN1649568A (en) 2005-08-03
JP2010138184A (en) 2010-06-24
SI1420759T1 (en) 2009-10-31
CA2457926A1 (en) 2003-03-13
NZ530987A (en) 2006-08-31
KR100970531B1 (en) 2010-07-16
MXPA04001875A (en) 2004-06-15
JP2005502675A (en) 2005-01-27
US20050147565A1 (en) 2005-07-07
AT430555T (en) 2009-05-15
CY1111726T1 (en) 2015-10-07
ES2361805T3 (en) 2011-06-22
HK1128428A1 (en) 2011-06-10
DK1420759T3 (en) 2009-08-03
EP2319494B1 (en) 2012-06-13
ZA200401419B (en) 2005-01-26

Similar Documents

Publication Publication Date Title
TW438604B (en) Fluticasone propionate pharmaceutical compositions
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
IL227966D0 (en) Vaccine composition
MXPA02011303A (en) Liquid pharmaceutical composition containing an erythropoietin derivate.
HU0102337A3 (en) Process for preparation of compositions for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the upper respiratory tract and/or the ear
PL360745A1 (en) Quinazoline derivatives for the treatment of tumours
TWI329108B (en) 17-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2414095A1 (en) Novel compounds
CA2443952A1 (en) Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
HU0402497A3 (en) Pharmaceutical compositions containing two activ ingredients and their uses
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
WO2004037773A8 (en) Phenethanolamine derivative for the treatment of respiratory diseases
IL164003A (en) Sulfonylamino-derivatives, compositions thereof, process of preparation and uses for the manufacture of medicaments for inhibiting histone deacetylase
TW200936590A (en) P38 inhibitors and methods of use thereof
IL163366A (en) Glucocorticoid mimetics, pharmaceutical compositions thereof and uses thereof for the preparation of pharmaceutical compositions
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
WO2004037768A3 (en) Phenethanolamine derivatives
CA2494010A1 (en) Modafinil polymorphic forms
YU37602A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HU0402264A3 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines process for preparing them, pharmaceutical compositions containing them and use thereof
LV12731A (en) Flash-melt oral dosage formulation
PT1326595E (en) Pharmaceutical composition understanding resveratrol for the treatment of inflammatory respiratory disturbles
CA2517517A1 (en) P38 inhibitors and methods of use thereof
PT1462100E (en) Composition comprising formoterol and a glucocorticosteroid

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees